Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
Protein & Cell
; (12): 634-643, 2017.
Article
in En
| WPRIM
| ID: wpr-756985
Responsible library:
WPRO
ABSTRACT
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (CRISPR/Cas9) system, an RNA-guided DNA targeting technology, is triggering a revolution in the field of biology. CRISPR/Cas9 has demonstrated great potential for genetic manipulation. In this review, we discuss the current development of CRISPR/Cas9 technologies for therapeutic applications, especially chimeric antigen receptor (CAR) T cell-based adoptive immunotherapy. Different methods used to facilitate efficient CRISPR delivery and gene editing in T cells are compared. The potential of genetic manipulation using CRISPR/Cas9 system to generate universal CAR T cells and potent T cells that are resistant to exhaustion and inhibition is explored. We also address the safety concerns associated with the use of CRISPR/Cas9 gene editing and provide potential solutions and future directions of CRISPR application in the field of CAR T cell immunotherapy. As an integration-free gene insertion method, CRISPR/Cas9 holds great promise as an efficient gene knock-in platform. Given the tremendous progress that has been made in the past few years, we believe that the CRISPR/Cas9 technology holds immense promise for advancing immunotherapy.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Recombinant Fusion Proteins
/
Receptors, Antigen, T-Cell
/
Allergy and Immunology
/
Clustered Regularly Interspaced Short Palindromic Repeats
/
Gene Editing
/
Genetics
/
Immunotherapy
/
Methods
Limits:
Animals
/
Humans
Language:
En
Journal:
Protein & Cell
Year:
2017
Type:
Article